Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year. In Western countries, the disease is relatively rare and acquired primarily in adulthood, whereas in Asia and most of Africa, chronic HBV infection is common and usually acquired perinatally or in childhood. More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality. Safe and effective vaccines against HBV infection have been available since 1982. The implementation of mass immunization programs, which have been recommended by the World Health Organization since 1991, have dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries. However, not all countries have adopted these recommendations and there remains a large number of persons that were infected with HBV prior to the implementation of immunization programs. Antiviral treatment is the only way to reduce morbidity and mortality from chronic HBV infection. Conventional interferon alfa and lamivudine have been the primary treatments to date. Conventional interferon alfa produces a durable response in a moderate proportion of patients but has undesirable side-effects and must be administered subcutaneously three times per week. Lamivudine also produces a response in a modest proportion of patients and causes few side-effects. However, prolonged treatment is often necessary to prevent relapse on cessation of therapy, and continuous treatment can lead to the development of lamivudine resistance. Promising emerging new treatments include adefovir, entecavir and peginterferon alfa-2a (40 kDa).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Carman, W. F., Hadziyannis, S., Mcgarvey, M. J., Jacyna, M. R., Karayiannis, P., Makris, A., & Thomas, H. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90713-7 · Cited by 1,200
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 840
Management of hepatitis B: 2000—Summary of a workshop
Lok, A. S., Heathcote, E. J., & Hoofnagle, J. H. (2001) · Gastroenterology · doi:10.1053/gast.2001.24839 · Cited by 776
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 689
Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26371 · Cited by 668
Unsafe injections in the developing world and transmission of bloodborne pathogens: a review.
Simonsen, L., Kane, A. D., Lloyd, J. L. E., et al. (1999) · PubMed · Cited by 619
Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
Glue, P. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110973 · Cited by 504
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00450.x · Cited by 475
Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection
Mahoney, F. J. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.351 · Cited by 446
Lok, A. S. F. (2002) · New England Journal of Medicine · doi:10.1056/nejm200205303462202 · Cited by 442
Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus
McMahon, B. J., Holck, P., Bulkow, L., & Snowball, M. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-9-200111060-00006 · Cited by 431
Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy
Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., & Hoofnagle, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-629 · Cited by 396
Kane, A., Lloyd, J., Zaffran, M., et al. (1999) · PubMed · Cited by 368
Ni, Y.-H., Chang, M.-H., Huang, L.-M., Chen, H.-L., Hsu, H.-Y., Chiu, T.-Y., Tsai, K.-S., & Chen, D.-S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-9-200111060-00009 · Cited by 365
Reddy, R. K., Wright, T. L., Pockros, P. J., Shiffman, M., Everson, G., Reindollar, R., Fried, M. W., Purdum, P. P., Jensen, D., Smith, C., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.21747 · Cited by 359
International trends and patterns of primary liver cancer
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., & Fraumeni, J. F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1456 · Cited by 349
Song, B.-C., Suh, D. J., Lee, H. C., Chung, Y.-H., & Lee, Y. S. (2000) · Hepatology · doi:10.1053/jhep.2000.16665 · Cited by 336
Chen, D.-S. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390190075023 · Cited by 333
Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M., & Bonino, F. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00266-5 · Cited by 331
Clinical Pharmacokinetics of Lamivudine
Johnson, M. A., Moore, K. H. P., Yuen, G. J., Bye, A., & Pakes, G. E. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00004 · Cited by 275
Epidemiology of hepatitis B virus infection in the Asia–Pacific region
Chen, C., Wang, L., & Yu, M. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02124.x · Cited by 259
Papatheodoridis, G. V., Manesis, E., & Hadziyannis, S. J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00094-5 · Cited by 246
Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., & Pastore, G. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80076-8 · Cited by 242
Seroepidemiology of Hepatitis B Virus Infection in Children: Ten Years of Mass Vaccination in Taiwan
Chen, H.-L. (1996) · JAMA · doi:10.1001/jama.1996.03540110060032 · Cited by 241
Fattovich, G., Giustina, G., Realdi, G., Corrocher, R., & Schalm, S. W. (1997) · Hepatology · doi:10.1002/hep.510260536 · Cited by 229
Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B
Manesis, E. K., & Hadziyannis, S. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.25524 · Cited by 216
Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.
Gust, I. D. (1996) · Gut · doi:10.1136/gut.38.suppl_2.s18 · Cited by 202
Epidemiology of Hepatocellular Carcinoma
Yu, M. C., Yuan, J.-M., Govindarajan, S., & Ross, R. K. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/371801 · Cited by 179
Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Fukuda, M., Koida, I., Arase, Y., Chayama, K., Murashima, N., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<827::aid-cncr5>3.0.co;2-g · Cited by 175
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
Malik, A. H., & Lee, W. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00007 · Cited by 167
de Man, R. A., Wolters, L. M. M., Nevens, F., Chua, D., Sherman, M., Lai, C. L., Gadano, A., Lee, Y., Mazzotta, F., Thomas, N., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26815 · Cited by 160
Hsu, H. M., Chen, D., Chuang, C. H., et al. (1988) · PubMed · Cited by 154
Characteristics of hepatocellular carcinoma in Italy
Stroffolini, T., Andreoné, P., Andriulli, A., Ascione, A., Craxì, A., Chiaramonte, M., Galante, D., Manghisi, O. G., Mazzanti, R., Medaglia, C., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80122-0 · Cited by 153
Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000)
Beutels, P. (2001) · Health Economics · doi:10.1002/hec.625 · Cited by 142
Stroffolini, T., Mele, A., Tosti, M. E., Gallo, G., Balocchini, E., Ragni, P., Santonastasi, F., Marzolini, A., Ciccozzi, M., & Moiraghi, A. R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80132-4 · Cited by 106
Delaney, W. E., Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T. G., Isom, H. C., Bock, C. –., Manns, M. P., Trautwein, C., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1705-1713.2001 · Cited by 94
Safety of blood supply for infectious diseases in Latin American countries, 1994-1997.
Schmuñis, G. A., Zicker, F., Cruz, J. R., & Cuchí, P. (2001) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.65.924 · Cited by 82
Kuper, H., Τζώνου, Α., Kaklamani, E., Hadziyannis, S. J., Tasopoulos, N., Λάγιου, Π., Trichopoulos, D., & Stuver, S. O. (2000) · Cancer Causes & Control · doi:10.1023/a:1008951901148 · Cited by 69
Risk Factors for Hepatocellular Carcinoma in Turkey
Uzunalımoǧlu, Ö., Yurdaydın, C., Çetınkaya, H., et al. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010705910858 · Cited by 66
Brooks, E. A., Lacey, L. F., Payne, S. L., & Miller, D. W. (2001) · PubMed · Cited by 36
Aguayo, Á., & Patt, Y. Z. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70175-6 · Cited by 31
Pokorski, R. J., & Ohlmer, U. (2001) · PubMed · Cited by 11
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Metadata
- Authors
- Lavanchy, D.
- Venue
- Journal of Viral Hepatitis
- Publisher
- Wiley
- Published
- 2004-02-20
- Volume
- 11
- Issue
- 2
- Pages
- 97-107
- ISSN
- 1352-0504 (ISSN-L)
- 1365-2893
- OpenAlex
- W2087564721
- Cited by
- 2,642
- References
- 51
- FWCI
- 45.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.